Eikon Acquires Broad Development Pipeline, Raises $106M in Series C Funding

Led by biopharma titan Roger Perlmutter, Eikon Therapeutics kicked off 2022 with a Series B financing worth $517.8 million. The Bay Area-based biotech made another splash Thursday, announcing a $106 million Series C raise and the acquisition of exclusive, global rights to several early- to mid-stage assets.